Pharmacokinetics and PK-PD modelling of danofloxacin in camel serum and tissue cage fluids

摘要: Abstract The pharmacokinetics and pharmacodynamics of danofloxacin were studied in the camel a two period cross-over study. After intravenous (i.v.) administration at dose rate 1.25 mg/kg, indicated high volume distribution (Vdarea=3.43 L/kg), relatively rapid clearance (0.44 L/kg/h) half-life 5.37 h. intramuscular (i.m.) dosing absorption was complete (F=114.5) (T(1/2)abs=0.12 h) terminal 5.71 h. Danofloxacin penetrated fairly slowly into both inflamed (exudate) non-inflamed (transudate) tissue cage fluids cleared from these fluids, elimination being least twice that for serum exudate transudate after i.v. i.m. dosing. antibacterial actions against pathogen Escherichia coli 0157-H7 determined by measurement minimum inhibitory concentration (MIC) vitro (single measurement) ex vivo measurements bacterial count nine times between one 48 h each serum, exudate, transudate. Using MIC data pharmacokinetic parameters, surrogate markers antimicrobial activity, Cmax/MIC, AUC/MIC T > MIC, all three fluids. AUC 24 h /MIC integrated with reduction to provide values producing bacteriostatic action (no change count), inhibition 50%, 99.9% (bactericidal action) bacteria. Mean 17.20, 20.07, 21.24, 68.37 h, respectively. To describe latter, introduction new term supplement bactericidal (MBC) is proposed, namely (MEC). A novel means designing drug dosage schedules evaluation clinical trials using activity bacteria together MIC90 pathogens.